


L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:874414 CAPLUS Full-text
DN 145:448575
TI Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine
AU Burgey, Christopher S.; Stump, Craig A.; Nguyen, Diem N.; Deng, James Z.; Quigley, Amy G.; Norton, Beth R.; Bell, Ian M.; Mosser, Scott D.; Salvatore, Christopher A.; Rutledge, Ruth Z.; Kane, Stefanie A.; Koblan, Kenneth S.; Vacca, Joseph P.; Graham, Samuel L.; Williams, Theresa M.
CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(19), 5052-5056
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
GI




AB In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, the authors have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone (I). In this regard, the authors have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g. II and III). These studies produced a potent analog II which overcomes the instability issues associated with the lead structure I. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented.

IT 844502-88-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(optimization of 4-substituted piperidine of benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists)

RN 844502-88-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 820214-69-5P 820214-71-9P 820214-73-1P
 820214-77-5P 820214-91-3P 820214-93-5P
 820214-95-7P 844502-89-2P 844502-90-5P
 844502-91-6P 844502-92-7P 844502-93-8P
 844502-94-9P 844502-95-0P 844502-96-1P
 844502-97-2P 913195-60-5P 913195-61-6P
 913195-62-7P 913195-63-8P 913195-64-9P
 913195-65-0P 913195-66-1P 913195-67-2P
 913195-74-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(optimization of 4-substituted piperidine of benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists)

RN 820214-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-77-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(7-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-91-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-

y1)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-93-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-4-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-95-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 844502-89-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-c]pyridin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 844502-90-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]pyridin-3-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 844502-91-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-92-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyrazin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-93-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 844502-94-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-

trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-95-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[3,4-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-96-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 844502-97-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[3,2-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913195-60-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(4-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913195-61-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-62-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[{(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]}- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-63-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-[1-[[[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 913195-64-9 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-[1-[[[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-

(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-65-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2,3-dihydro-5-(methylsulfonyl)-2-oxo-1H-benzimidazol-1-yl]-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-66-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-7-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-67-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-4-oxido-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 913195-74-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-naphth[1,2-d]imidazol-3-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 820214-24-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(optimization of 4-substituted piperidine of benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists)

RN 820214-24-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:315123 CAPLUS Full-text
 DN 144:460321
 TI Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead
 AU Williams, Theresa M.; Stump, Craig A.; Nguyen, Diem N.; Quigley, Amy G.; Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blair; Wan, Bang-Lin; Della Penna, Kimberly; Kunapuli, Priya; Kane, Stefanie A.; Koblan, Ken S.; Mosser, Scott D.; Rutledge, Ruth Z.; Salvatore, Christopher; Fay, John F.; Vacca, Joseph P.; Graham, Samuel L.
 CS Department of Medicinal Chemistry, Merck & Co., West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2595-2598
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 144:460321
 AB High-throughput screening of the Merck sample collection identified a benzodiazepinone tetralin-spirohydantoin as a CGRP receptor antagonist with micromolar activity. Comparing the structure of this compound with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinazolinone, CGRP receptor Ki = 44 nM and IC50 = 38 nM. This compound was orally bioavailable in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine.
 IT 820214-24-2P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)
 RN 820214-24-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 820214-30-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)
 RN 820214-30-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA

INDEX NAME)



IT 820214-20-8P 820214-22-0P 820214-23-1P
820214-52-6P 820214-67-3P 820214-69-5P
886854-33-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)

RN 820214-20-8 CAPPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-22-0 CAPPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-23-1 CAPPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-52-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 820214-67-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)



RN 820214-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 886854-33-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-

1H-1, 4-benzodiazepin-3-yl]-4-(1, 4-dihydro-1-methyl-2-oxo-3(2H)-
quinazolinyl)- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:136493 CAPLUS Full-text

DN 142:240471

TI Preparation of benzodiazepine derivatives as CGRP receptor antagonists

IN Burgey, Christopher S.; Stump, Craig A.; Williams, Theresa M.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 79 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013894	A2	20050217	WO 2004-US20209	20040624
	WO 2005013894	A3	20060302		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004263080	A1	20050217	AU 2004-263080	20040624
	CA 2529196	A1	20050217	CA 2004-2529196	20040624
	EP 1641423	A2	20060405	EP 2004-776997	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1842526	A	20061004	CN 2004-80017996	20040624
	JP 2007516183	T	20070621	JP 2006-517599	20040624
	US 2006135511	A1	20060622	US 2005-562297	20051222
PRAI	US 2003-482854P	P	20030626		
	WO 2004-US20209	W	20040624		
OS	CASREACT 142:240471; MARPAT 142:240471				
GI					



I



II

AB Benzodiazepine derivs. of formula I [R1 = H, alkyl, cycloalkyl, aryl, etc.; R2 = H, alkyl, cycloalkyl, aryl, etc.; R3 = H, alkyl, CO2H, alkoxy carbonyl; R4 = H, alkyl, cycloalkyl, aryl, etc.; R5 = H, alkyl, cycloalkyl, etc.; n = 1-4; m = 1-9; p = 1-4; W = O, (substituted) NH, (substituted) CH2; X = C, S; Y = O, NCONH2, etc.; G, J = N, NCH2, etc.; Q, T, U, V = CH, N; with provisos] are prepared as antagonists of CGRP receptors, and are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache,

migraine and cluster headache. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved. Thus, II was prepared in several steps. The prepared compds. had IC₅₀ values < 50 μM against CGRP receptor.

IT 844502-88-1P 844502-89-2P 844502-90-5P
 844502-91-6P 844502-92-7P 844502-93-8P
 844502-94-9P 844502-95-0P 844502-96-1P
 844502-97-2P 844502-98-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzodiazepines as CGRP receptor antagonists)

RN 844502-88-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-89-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-c]pyridin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-90-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]pyridin-3-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-91-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-92-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyrazin-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-93-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-94-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-95-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[3,4-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-96-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-97-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[3,2-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 844502-98-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-pyrido[2,3-d]-1,3-diazepin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:14369 CAPLUS Full-text

DN 142:114110

TI Preparation of benzodiazepine CGRP receptor antagonists

IN Burgey, Christopher S.; Stump, Craig A.; Williams, Theresa M.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 86 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000807	A2	20050106	WO 2004-US20206	20040624
	WO 2005000807	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004252150	A1	20050106	AU 2004-252150	20040624
	CA 2529227	A1	20050106	CA 2004-2529227	20040624
	EP 1641781	A2	20060405	EP 2004-776996	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1812982	A	20060802	CN 2004-80017952	20040624
	JP 2007516182	T	20070621	JP 2006-517597	20040624
	US 2006148790	A1	20060706	US 2005-562298	20051222
	US 7196079	B2	20070327		
PRAI	US 2003-482674P	P	20030626		
	WO 2004-US20206	W	20040624		
OS	CASREACT 142:114110; MARPAT 142:114110				
GI					



AB Title compds. I [R1 = H, alk(en/yn)yl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R7 = H, alk(en/yn)yl, etc.; W = O, amino, alkyl; X = C, S; Y = O, NCN, etc.; R3 = H, alkyl, CN, etc.; R6 = H, alkyl, cycloalkyl, etc.; G-J = N, N-alkyl,

etc.] are prepared. For instance, II is prepared from (R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine oxalate, p-nitrophenylchloroformate and 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one hydrochloride. Compds. I exhibit affinity for the CGRP receptor with an IC₅₀ of less than 50μM. I, alone or in combination with other agents, are useful for the treatment of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.


IT 820214-20-8P 820214-21-9P 820214-22-0P
 820214-23-1P 820214-24-2P 820214-25-3P
 820214-26-4P 820214-27-5P 820214-28-6P
 820214-29-7P 820214-30-0P 820214-31-1P
 820214-32-2P 820214-33-3P 820214-34-4P
 820214-35-5P 820214-36-6P 820214-37-7P
 820214-38-8P 820214-39-9P 820214-40-2P
 820214-41-3P 820214-42-4P 820214-43-5P
 820214-44-6P 820214-45-7P 820214-46-8P
 820214-47-9P 820214-48-0P 820214-49-1P
 820214-50-4P 820214-51-5P 820214-52-6P
 820214-53-7P 820214-54-8P 820214-55-9P
 820214-57-1P 820214-59-3P 820214-61-7P
 820214-63-9P 820214-65-1P 820214-67-3P
 820214-69-5P 820214-71-9P 820214-73-1P
 820214-75-3P 820214-77-5P 820214-79-7P
 820214-81-1P 820214-84-4P 820214-86-6P
 820214-88-8P 820214-91-3P 820214-93-5P
 820214-95-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzodiazepine CGRP receptor antagonists for headaches)

RN 820214-20-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-21-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-22-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-23-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-24-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-25-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-26-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-7-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-27-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-8-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-28-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-9-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-29-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1-propyl-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-30-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 820214-31-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(1-butyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 820214-32-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-33-3 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-34-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(4,4,4-trifluorobutyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-35-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-36-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-[(4-methoxyphenyl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-37-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(2-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 820214-38-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(3-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-39-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(4-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)




RN 820214-40-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)




RN 820214-41-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)




RN 820214-42-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)




RN 820214-43-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)




RN 820214-44-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 820214-45-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 820214-46-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-5-cyclohexyl-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-47-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-5-(1-methylethyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1,7-dimethyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 820214-49-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1,8-dimethyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 820214-50-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3S)-5-(1,1-dimethylethyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-51-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-52-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-53-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (CA INDEX NAME)




RN 820214-54-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl ester (CA INDEX NAME)




RN 820214-55-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl ester (CA INDEX NAME)




RN 820214-57-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (CA INDEX NAME)



RN 820214-59-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (CA INDEX NAME)



RN 820214-61-7 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-N'-(*(3R)*-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-63-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[*(3S)*-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-65-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-1-(4-aminobutyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(CA INDEX NAME)

Absolute stereochemistry.



RN 820214-67-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(CA INDEX NAME)



RN 820214-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 820214-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-77-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(7-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-79-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-81-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-[2,3-dihydro-2-oxo-6-(trifluoromethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-84-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 3-[1-[[[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-86-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 3-[1-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-88-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2,3-dihydro-6-(methylsulfonyl)-2-oxo-1H-benzimidazol-1-yl]-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-91-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-93-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-4-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-95-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 820215-30-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzodiazepine CGRP receptor antagonists for headaches)

RN 820215-30-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-1-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



=> d 12; d his; log y

L2 HAS NO ANSWERS

L1 STR



G1 C, O, N

G2 C, S

G3 C, N

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

(FILE 'REGISTRY' ENTERED AT 12:34:08 ON 26 MAR 2008)

DEL HIS Y

L1 STRUCTURE uploaded

L2 QUE L1

L3 2 S L2

L4 77 S L2 FUL

FILE 'CAPLUS' ENTERED AT 12:35:37 ON 26 MAR 2008

L5 4 S L4

FILE 'MARPAT' ENTERED AT 12:36:21 ON 26 MAR 2008

L6 1 S L2

L7 2 S L2 FUL

L8 0 S L7 NOT L5

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

125.26

326.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

0.00

-3.20

STN INTERNATIONAL LOGOFF AT 12:37:04 ON 26 MAR 2008